In a patient with rheumatoid arthritis and interstitial lung disease, should methotrexate be avoided and can mycophenolate mofetil be used as the disease‑modifying therapy?

Methotrexate Should Be Avoided and Mycophenolate Mofetil Is the Preferred First-Line Therapy for RA-ILD

In patients with rheumatoid arthritis and interstitial lung disease, methotrexate should be avoided as first-line ILD treatment, and mycophenolate mofetil is conditionally recommended as the preferred disease-modifying therapy. 1

Treatment Algorithm for RA-ILD

First-Line Therapy Selection

Mycophenolate mofetil is the preferred first-line option across all systemic autoimmune rheumatic disease-associated ILD, including RA-ILD. 1 The 2023 ACR/CHEST guidelines explicitly list mycophenolate as the top-ranked therapy based on head-to-head voting hierarchies, with additional first-line options including:

• Azathioprine (second-tier preferred option)
• Rituximab (preferred, particularly if inflammatory arthritis needs concurrent treatment)
• Cyclophosphamide (additional option, concerns about toxicity)

1

Why Methotrexate Should Be Avoided

The guidelines conditionally recommend against methotrexate as first-line ILD treatment for all SARD-ILD, including RA-ILD. 1 This recommendation is based on:

• Lack of evidence demonstrating benefit for ILD outcomes 1
• Risk of idiosyncratic methotrexate pneumonitis, though rare 1
• FDA warnings about methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis that may occur at any time during therapy and is not always fully reversible, with reported fatalities 2

Critical Nuance About Methotrexate

There is an important distinction between avoiding methotrexate for ILD treatment versus continuing it for joint disease:

• Methotrexate may be continued in patients already receiving it for extrapulmonary RA manifestations if ILD is stable 1
• Observational data suggest methotrexate does not worsen existing ILD and may even have a protective association (pooled OR 0.43 for developing RA-ILD in MTX users) 3, 4, 5
• However, methotrexate should be stopped if there is concern for methotrexate pneumonitis, and some experts would discontinue if ILD develops while on methotrexate 1

This creates a clinical paradox: while retrospective data suggest methotrexate doesn't increase RA-ILD risk 3, 4, 5, the guidelines prioritize other agents with more evidence of ILD benefit, and the FDA label carries strong warnings about pulmonary toxicity 2.

Mycophenolate Mofetil Dosing and Monitoring

Standard dosing: Typically initiated at lower doses and titrated up to 2-3 grams daily in divided doses, based on tolerability.

Monitoring requirements:

• CBC with differential at baseline and regularly (every 2-4 weeks initially, then monthly)
• Comprehensive metabolic panel
• Pregnancy testing (teratogenic risk)

1

Evidence for mycophenolate: Data from SSc-ILD trials show similar outcomes to cyclophosphamide but with more favorable adverse effect profile. 1 A large diverse cohort study demonstrated MMF improved FVC% by 4.9-7.3% at 52-156 weeks and was well tolerated with low discontinuation rates. 6

Management of Progressive RA-ILD

If ILD progresses despite first-line therapy, the guidelines recommend:

1. Switch to or add: Mycophenolate, rituximab, cyclophosphamide, or nintedanib 1
2. Consider adding pirfenidone specifically for RA-ILD (this is unique to RA-ILD, not recommended for other SARD-ILD) 1
3. Consider tocilizumab for progressive RA-ILD 1

Rapidly Progressive ILD

For rapidly progressive RA-ILD, the approach differs significantly:

• Conditionally recommend against methotrexate as first-line RP-ILD treatment 1
• Recommended therapies: Pulse IV methylprednisolone plus rituximab, cyclophosphamide, IVIG, mycophenolate, calcineurin inhibitors, or JAK inhibitors 1
• Consider early lung transplant referral 1

Common Pitfalls to Avoid

1. Do not reflexively stop methotrexate in stable RA-ILD patients already on it for joint disease—evaluate for methotrexate pneumonitis versus RA-ILD progression
2. Do not use long-term glucocorticoids as primary ILD therapy (conditionally recommended against) 1
3. Do not delay treatment initiation in symptomatic, progressing, or high-risk patients
4. Do not assume UIP pattern precludes immunosuppression—mycophenolate may stabilize even UIP-pattern RA-ILD 6

Pan American League Guidelines Divergence

The 2026 PANLAR guidelines 7 conditionally recommend methotrexate for RA-ILD treatment, creating a direct contradiction with ACR/CHEST guidelines. However, the ACR/CHEST guidelines should take precedence as they:

• Are more recent (2023 vs 2026 publication but 2023 evidence base)
• Are specifically focused on ILD management
• Represent joint pulmonology and rheumatology consensus
• Provide more granular ILD-specific recommendations

1

The bottom line: Start mycophenolate mofetil as first-line therapy for RA-ILD, avoid initiating methotrexate for ILD treatment, and carefully evaluate whether to continue methotrexate in patients already receiving it for joint disease.